MiNK Therapeutics reported Q1 2026 financial results with $9.5M cash, $2.7M net loss, and advanced agenT-797 into randomized Phase 2 trial for severe acute lung injury.
Key takeaways
Cash and equivalents: $9.5M as of March 31, 2026, down from $13.4M at year-end 2025.
Q1 2026 net loss $2.7M or ($0.57) per share vs. $2.8M or ($0.70) per share in Q1 2025.
Initiated randomized Phase 2 trial of agenT-797 in severe acute lung injury, data expected H2 2026.
AACR/ASGCT data showed context-dependent iNKT activity in cancer and ARDS patients.
C-Further collaboration provides up to $1.1M non-dilutive funding for PRAME-targeted iNKT therapy.
Repaid $5.2M Agenus convertible note and raised $3.0M via at-the-market sales.